Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean Region: it takes a village…
Open Access
- 21 October 2021
- journal article
- research article
- Published by BMJ in BMJ Global Health
- Vol. 6 (10), e007195
- https://doi.org/10.1136/bmjgh-2021-007195
Abstract
Congenital adrenal hyperplasia (CAH), if untreated, carries high morbidity and mortality. A higher incidence of CAH is expected in countries where consanguinity is common, such as in the countries of the WHO Eastern Mediterranean Region (EMRO). CAH is managed through lifelong treatment with fludrocortisone and hydrocortisone. In this analysis, performed in the 22 EMRO countries and territories plus Algeria, we review which countries offer a neonatal screening programme for CAH and describe the barriers and opportunities to access oral fludrocortisone and oral and injectable hydrocortisone. Neonatal CAH screening was only available nationally in Qatar, Kuwait and partially in Lebanon and Saudi Arabia. We reviewed the national lists of essential medicines (NEMLs) and found that 13/23 (57%) countries included fludrocortisone and 18/23 (78%) included oral hydrocortisone. Fludrocortisone was not included by any of the low-income countries and oral hydrocortisone was only included by one low-income country. We then contacted paediatric endocrinologists in each country to assess perceived availability of these medicines. Overall, there was a relatively good consistency between inclusion of fludrocortisone and hydrocortisone in the NEML and their actual availability in a country. We propose several mechanisms to improve access, including prequalification by the WHO, a common registration process for groups of countries, pooled procurement, working with local pharmaceutical companies, special access status for medicines not yet registered in a country and compounding. We suggest that access to medicines requires a collaboration between health professionals, families of patients, health authorities, pharmaceutical companies and the WHO.This publication has 20 references indexed in Scilit:
- Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based studyBMC Pediatrics, 2015
- Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A five-year retrospective study in the Children's Hospital of Damascus, SyriaQatar Medical Journal, 2015
- Current status of newborn screening worldwide: 2015Seminars in Perinatology, 2015
- Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011.Eastern Mediterranean Health Journal, 2014
- Incidence and clinical features of congenital adrenal hyperplasia in Great BritainArchives of Disease in Childhood, 2012
- Consanguinity, human evolution, and complex diseasesProceedings of the National Academy of Sciences of the United States of America, 2010
- Dexamethasone Therapy of Congenital Adrenal Hyperplasia and the Myth of the “Growth Toxic” GlucocorticoidInternational Journal of Pediatric Endocrinology, 2010
- Low-Dose Dexamethasone Therapy from Infancy of Virilizing Congenital Adrenal HyperplasiaInternational Journal of Pediatric Endocrinology, 2009
- Low-Dose Dexamethasone Therapy from Infancy of Virilizing Congenital Adrenal HyperplasiaInternational Journal of Pediatric Endocrinology, 2009
- Stability of fludrocortisone acetate solutions prepared from tablets and powder.European Journal of Pharmaceutics and Biopharmaceutics, 2003